CXCR1/2 Dual-Inhibitor Ladarixin Reduces Tumour Burden and Promotes Immunotherapy Response in Pancreatic Cancer

A set of preclinical models was obtained by engrafting mouse PDAC-derived cells into syngeneic immune-competent mice, as well as by orthotopically transplanting patient-derived PDAC tumour into human immune-system-reconstituted mice.